Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy

Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn R. Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma and C. Willemien Menke-van der Houven van Oordt
Journal of Nuclear Medicine October 2020, jnumed.120.251611; DOI: https://doi.org/10.2967/jnumed.120.251611
Lemonitsa H. Mammatas
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lemonitsa H. Mammatas
Maqsood Yaqub
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maqsood Yaqub
N. Harry Hendrikse
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto S. Hoekstra
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Otto S. Hoekstra
Richard J. Honeywell
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard J. Honeywell
Robert C. Schuit
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert C. Schuit
Martijn R. Meijerink
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martijn R. Meijerink
Lothar A. Schwarte
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lothar A. Schwarte
Godefridus J. Peters
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Godefridus J. Peters
Henk M.W. Verheul
2 Radboud University Medical Center, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Henk M.W. Verheul
Adriaan A. Lammertsma
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adriaan A. Lammertsma
C. Willemien Menke-van der Houven van Oordt
1 Cancer Center Amsterdam, Amsterdam UMC, VUmc University Medical Center Amsterdam, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Willemien Menke-van der Houven van Oordt
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Sorafenib leads to clinical benefit in a subgroup of patients, while all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether 11C-sorafenib and 15O-H2O PET have potential to predict treatment efficacy. Methods: In this prospective exploratory study, 8 patients with advanced solid malignancies and an indication for sorafenib treatment were included. Microdose 11C-sorafenib and perfusion 15O-H2O dynamic PET scans were performed before and after two weeks of sorafenib therapy. The main objective was to assess whether tumor 11C-sorafenib uptake predicts sorafenib concentrations during therapy in corresponding tumor biopsies measured with liquid chromatography tandem mass spectrometry (LC-MS/MS). Secondary objectives included the association of 11C-sorafenib PET, perfusion 15O-H2O PET and sorafenib concentrations after therapeutic dosing with response. Results: 11C-sorafenib PET did not predict sorafenib concentrations in tumor biopsies during therapy. In addition, sorafenib plasma and tumor concentrations, were not associated with clinical outcome in this exploratory study. Higher 11C-sorafenib accumulation in tumors at baseline and day 14 of treatment showed association with poorer prognosis and was correlated with tumor perfusion (rs = 0.671, P = 0.020). Interestingly, a decrease in tumor perfusion measured with 15O-H2O PET after only 14 days of therapy showed an association with response, with a decrease in tumor perfusion of 56% ± 23% (mean ± SD) versus 18% ± 32% in patients with stable and progressive disease, respectively. Conclusion: Microdose 11C-sorafenib PET did not predict intratumoral sorafenib concentrations after therapeutic dosing, but the association between a decrease in tumor perfusion and clinical benefit warrants further investigation.

  • Oncology: General
  • PET/CT
  • Radiopharmaceuticals
  • 11C-sorafenib
  • 15O-H2O
  • Imaging biomarker
  • PET/CT
  • intratumor drug concentration
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy
Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn R. Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma, C. Willemien Menke-van der Houven van Oordt
Journal of Nuclear Medicine Oct 2020, jnumed.120.251611; DOI: 10.2967/jnumed.120.251611

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy
Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn R. Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma, C. Willemien Menke-van der Houven van Oordt
Journal of Nuclear Medicine Oct 2020, jnumed.120.251611; DOI: 10.2967/jnumed.120.251611
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis
  • Simulation of low dose protocols for myocardial perfusion 82Rubidium imaging
  • QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Show more Clinical Investigations (Human)

Clinical (Oncology: Other)

  • Radioguided Surgery (Letter to the Editor)
  • Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
  • State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?
Show more Clinical (Oncology: Other)

Similar Articles

Keywords

  • Oncology: General
  • PET/CT
  • radiopharmaceuticals
  • 11C-sorafenib
  • 15O-H2O
  • Imaging Biomarker
  • intratumor drug concentration
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire